Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer

Takiguchi,Soichi; Inoue,Kazuko; Matsusue,Kimihiko; Furukawa,Masayuki; Teramoto,Norihiro; Iguchi,Haruo

doi:10.3892/ijo.2017.3992

Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer

Authors:
- Soichi Takiguchi
- Kazuko Inoue
- Kimihiko Matsusue
- Masayuki Furukawa
- Norihiro Teramoto
- Haruo Iguchi
View Affiliations

Affiliations: Clinical Research Institute, National Kyushu Cancer Center, Fukuoka 811-1395, Japan, Department of Hygiene Chemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan, Department of Hepato-Biliary-Pancreatology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan, Division of Pathology, National Hospital Organization Shikoku Cancer Center, Matsuyama 791-0280, Japan, Clinical Research Institute, National Hospital Organization Shikoku Cancer Center, Matsuyama 791-0280, Japan
Published online on: May 11, 2017 https://doi.org/10.3892/ijo.2017.3992
Pages: 184-192

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Peritoneal dissemination is a frequent occurrence in pancreatic cancer, which is associated with a poor prognosis. MET is associated with the progression of pancreatic cancer; therefore, we evaluated the effect of a MET inhibitor, crizotinib, on peritoneal dissemination of pancreatic cancer. Crizotinib inhibited the growth of 8 pancreatic cancer cell lines with the IC50 ranging from 1.4 to 4.3 µM. Invasion of the pancreatic cancer cell line Suit-2, was suppressed in vitro at a concentration of 1.0 µM, which is sufficient for the inhibition of MET phosphorylation. This effect on cell invasion was also recapitulated by the reduction of MET expression in Suit-2 with siRNA. Crizotinib also inhibited RhoA activation in addition to MET phosphorylation. We further evaluated the effect of crizotinib on peritoneal dissemination of pancreatic cancer in vivo. Crizotinib reduced tumor burden and ascites accumulation due to development of peritoneal dissemination after inoculation of Suit-2. Taken together, crizotinib may be a potent drug for treating peritoneal dissemination of pancreatic cancer by inhibiting cancer cell proliferation and invasion, at least in part through the suppression of HGF/MET signaling and RhoA activation.

View Figures

View References

1	Kleeff J, Michalski C, Friess H and Büchler MW: Pancreatic cancer: From bench to 5-year survival. Pancreas. 33:111–118. 2006. View Article : Google Scholar : PubMed/NCBI
2	Hidalgo M: Pancreatic cancer. N Engl J Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
3	Ryan DP, Hong TS and Bardeesy N: Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049. 2014. View Article : Google Scholar : PubMed/NCBI
4	Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar : PubMed/NCBI
5	Ueno H, Kiyosawa K and Kaniwa N: Pharmacogenomics of gemcitabine: Can genetic studies lead to tailor-made therapy? Br J Cancer. 97:145–151. 2007. View Article : Google Scholar : PubMed/NCBI
6	Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
7	Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
8	Von Hoff DD, Goldstein D and Renschler MF: Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. N Engl J Med. 370:479–480. 2014.PubMed/NCBI
9	Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, et al: FOLFIRINOX for locally advanced pancreatic cancer: A systematic review and patient-level meta-analysis. Lancet Oncol. 17:801–810. 2016. View Article : Google Scholar : PubMed/NCBI
10	Gherardi E, Birchmeier W, Birchmeier C and Vande Woude G: Targeting MET in cancer: Rationale and progress. Nat Rev Cancer. 12:89–103. 2012. View Article : Google Scholar : PubMed/NCBI
11	Di Renzo MF, Poulsom R, Olivero M, Comoglio PM and Lemoine NR: Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res. 55:1129–1138. 1995.PubMed/NCBI
12	Birchmeier C, Birchmeier W, Gherardi E and Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 4:915–925. 2003. View Article : Google Scholar : PubMed/NCBI
13	Kang Y and Massagué J: Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
14	Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
15	Gherardi E and Stoker M: Hepatocyte growth factor - scatter factor: Mitogen, motogen, and met. Cancer Cells. 3:227–232. 1991.PubMed/NCBI
16	Ridley AJ, Comoglio PM and Hall A: Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells. Mol Cell Biol. 15:1110–1122. 1995. View Article : Google Scholar : PubMed/NCBI
17	Wells CM, Ahmed T, Masters JR and Jones GE: Rho family GTPases are activated during HGF-stimulated prostate cancer-cell scattering. Cell Motil Cytoskeleton. 62:180–194. 2005. View Article : Google Scholar : PubMed/NCBI
18	Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, et al: An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67:4408–4417. 2007. View Article : Google Scholar : PubMed/NCBI
19	Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B and Los G: Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 6:3314–3322. 2007. View Article : Google Scholar : PubMed/NCBI
20	Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, Koup JR, Smith BJ and Koudriakova T: Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos. 36:1267–1274. 2008. View Article : Google Scholar : PubMed/NCBI
21	Timofeevski SL, McTigue MA, Ryan K, Cui J, Zou HY, Zhu JX, Chau F, Alton G, Karlicek S, Christensen JG, et al: Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry. 48:5339–5349. 2009. View Article : Google Scholar : PubMed/NCBI
22	Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V, Tabruyn SP, You WK, Chapman HA, Christensen JG, et al: Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov. 2:270–287. 2012. View Article : Google Scholar : PubMed/NCBI
23	Zheng X, He K, Zhang L and Yu J: Crizotinib induces PUMA-dependent apoptosis in colon cancer cells. Mol Cancer Ther. 12:777–786. 2013. View Article : Google Scholar : PubMed/NCBI
24	Surriga O, Rajasekhar VK, Ambrosini G, Dogan Y, Huang R and Schwartz GK: Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model. Mol Cancer Ther. 12:2817–2826. 2013. View Article : Google Scholar : PubMed/NCBI
25	Zhou Y, Zhao C, Gery S, Braunstein GD, Okamoto R, Alvarez R, Miles SA, Doan NB, Said JW, Gu J, et al: Off-target effects of c-MET inhibitors on thyroid cancer cells. Mol Cancer Ther. 13:134–143. 2014. View Article : Google Scholar
26	Avan A, Caretti V, Funel N, Galvani E, Maftouh M, Honeywell RJ, Lagerweij T, Van Tellingen O, Campani D, Fuchs D, et al: Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma. Cancer Res. 73:6745–6756. 2013. View Article : Google Scholar : PubMed/NCBI
27	Zhou W, Jubb AM, Lyle K, Xiao Q, Ong CC, Desai R, Fu L, Gnad F, Song Q, Haverty PM, et al: PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. J Pathol. 234:502–513. 2014. View Article : Google Scholar : PubMed/NCBI